Hanyu Jiang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6092944/publications.pdf

Version: 2024-02-01

38	803	516561	552653
papers	citations	h-index	g-index
39	39	39	853
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction. Cancer Imaging, 2019, 19, 22.	1.2	90
2	Gadoxetic acid disodium–enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A metaâ€analysis. Liver Transplantation, 2017, 23, 1505-1518.	1.3	71
3	Radiomics in liver diseases: Current progress and future opportunities. Liver International, 2020, 40, 2050-2063.	1.9	70
4	Liver fibrosis staging with diffusion-weighted imaging: a systematic review and meta-analysis. Abdominal Radiology, 2017, 42, 490-501.	1.0	47
5	Diffusion kurtosis imaging (DKI) of hepatocellular carcinoma: correlation with microvascular invasion and histologic grade. Quantitative Imaging in Medicine and Surgery, 2019, 9, 590-602.	1.1	42
6	Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. Cancer Imaging, 2019, 19, 84.	1.2	36
7	Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Deep Learning: A Multi-Center and Prospective Validation Study. Cancers, 2021, 13, 2368.	1.7	36
8	Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma?. European Journal of Radiology, 2020, 132, 109312.	1.2	34
9	CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. Radiology, 2022, 302, 326-335.	3.6	32
10	Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: A prospective study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 806-817.	0.7	31
11	Predicting microvascular invasion in hepatocellular carcinoma: A dualâ€institution study on gadoxetate disodiumâ€enhanced <scp>MRI</scp> . Liver International, 2022, 42, 1158-1172.	1.9	30
12	Noninvasive prediction of HCC with progenitor phenotype based on gadoxetic acid-enhanced MRI. European Radiology, 2020, 30, 1232-1242.	2.3	28
13	LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid–enhanced MRI for early recurrence risk stratification after curative resection. European Radiology, 2021, 31, 2289-2302.	2.3	27
14	Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid–enhanced magnetic resonance imaging. European Radiology, 2021, 31, 7696-7704.	2.3	23
15	Non-invasive in vivo Imaging Grading of Liver Fibrosis. Journal of Clinical and Translational Hepatology, 2018, 6, 1-10.	0.7	22
16	Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection. Annals of Translational Medicine, 2020, 8, 870-870.	0.7	22
17	Deep learningâ€based Al model for signetâ€ring cell carcinoma diagnosis and chemotherapy response prediction in gastric cancer. Medical Physics, 2022, 49, 1535-1546.	1.6	17
18	Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation. Annals of Translational Medicine, 2020, 8, 388-388.	0.7	16

#	Article	IF	CITATIONS
19	Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. Cancer Medicine, 2019, 8, 5399-5413.	1.3	15
20	Radiomics in prostate cancer: basic concepts and current state-of-the-art. Chinese Journal of Academic Radiology, 2020, 2, 47-55.	0.4	15
21	Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. European Radiology, 2021, 31, 3638-3648.	2.3	15
22	Impact of Reference Standard on CT, MRI, and Contrast-enhanced US LI-RADS Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. Radiology, 2022, 303, 544-545.	3.6	15
23	Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis. Radiology, 2021, 300, 361-368.	3.6	11
24	Artificial Intelligence in the Imaging of Gastric Cancer: Current Applications and Future Direction. Frontiers in Oncology, $2021, 11, 631686$.	1.3	9
25	Prognostic implications of <scp>CT</scp> / <scp>MRI Llâ€RADS</scp> in hepatocellular carcinoma: State of the art and future directions. Liver International, 2022, 42, 2131-2144.	1.9	8
26	Dataâ€Driven Modification of the <scp>Llâ€RADS</scp> Major Feature System on Gadoxetate Disodiumâ€Enhanced <scp>MRI</scp> : Toward Better Sensitivity and Simplicity. Journal of Magnetic Resonance Imaging, 2022, 55, 493-506.	1.9	6
27	Imaging methods for surgical revascularization in patients with moyamoya disease: an updated review. Neurosurgical Review, 2022, 45, 343-356.	1.2	6
28	Modifying <scp>Llâ€RADS</scp> on Gadoxetate Disodiumâ€Enhanced <scp>MRI</scp> : A Secondary Analysis of a Prospective Observational Study. Journal of Magnetic Resonance Imaging, 2022, 56, 399-412.	1.9	6
29	Assessing Liver Function in Liver Tumors Patients: The Performance of T1 Mapping and Residual Liver Volume on Gd-EOBDTPA-Enhanced MRI. Frontiers in Medicine, 2020, 7, 215.	1.2	5
30	Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study. European Radiology, 2022, 32, 7578-7589.	2.3	5
31	Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System. European Journal of Radiology, 2022, 154, 110397.	1.2	4
32	Noninvasive imaging assessment of portal hypertension: where are we now and where does the future lie?. Expert Review of Molecular Diagnostics, 2021, 21, 343-345.	1.5	3
33	Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 382-394.	0.7	2
34	Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT. Annals of Surgical Oncology, 2022, , 1.	0.7	2
35	New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. Frontiers in Oncology, 2022, 12, 812832.	1.3	1
36	Advances in artificial intelligence techniques drive the application of radiomics in the clinical research of hepatocellular carcinoma., 2022, 1, 49-54.		1

#	Article	lF	CITATIONS
37	ASO Author Reflections: Characterizing the Genomic Alterations in Hepatocellular Carcinoma by Contrast-Enhanced CT. Annals of Surgical Oncology, 2022, , 1.	0.7	O
38	ASO Visual Abstract: Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma—A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT. Annals of Surgical Oncology, 2022, , 1.	0.7	0